Eli Lilly Hits $1 Trillion Valuation on Weight-Loss Drug Demand

Imagine a single drug reshaping the entire pharmaceutical industry. Eli Lilly's breakthrough obesity drugs have propelled its historic $1 trillion valuation. Fueled by its blockbuster drugs Mounjaro and Zepbound, Lilly's stock has soared over 75% since late 2023, far outpacing the S&P 500. This metabolic health franchise now generates over $10 billion per quarter, making up more than half of the company's total revenue and cementing its dominance over rival Novo Nordisk. This milestone places Lilly among elite tech giants, offering investors a powerful new "Magnificent Seven" alternative. This isn't just about weight loss; it's transforming treatment for type 2 diabetes and setting the stage for a new oral pill, orforglipron, to reach millions more.